吉西他滨联合奈达铂与吉西他滨联合顺铂治疗老年晚期非小细胞肺癌的临床研究

目的：评估吉西他滨联合奈达铂与吉西他滨联合顺铂治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效和不良反应。方法：经病理学或细胞学确诊的晚期非小细胞肺癌患者90例,随机分为两组,每组各45例。GN组：吉西他滨（Gem）800mg/m^2,第1、8、15天静注,静脉滴注30分钟,奈达铂（NDP）80-100mg/m^2,静滴,第1天,滴注时间不少于1小时,每3周重复;GP组：吉西他滨（Gem）800mg/m^2,第1、8、15天静注,静脉滴注30分钟,顺铂（DDP）25mg/m^2,静滴,第1-3天,每28天为一个周期。治疗2周期评价疗效,每周期评价不良反应。结果：两组有效率分别为37.8%和40.0%,疾病控制率分别为77.8%和80.0%,中位生存期分别为8.8个月和9.0个月,差异均无显著性（P〉0.05）。GN方案组骨髓抑制尤其是血小板减少略高于GP方案组,但无显著性差异（P〉0.05）;GN方案组消化道反应为35.6%,GP方案组为84.4%,有显著性差异（P〈0.05）。结论：GN和GP方案均为治疗老年晚期NSCLC的有效方案,两方案疗效、疾病控制率及中位生存期均相近,但GN方案消化道反应较GP方案明显较轻,GN方案组患者耐受性更好。

Clinical study on gemcitabine combined with nedaplatin or cisplatin in the treatment of advanced non-small cell lung cancer

Objective：To evaluate the therapeutic effect and toxic reaction of gemcitabine（Gem） combined with nedaplatin（NDP） or cisplatin in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods： A total of 90 patients who had been confirmed as having advanced NSCLC by pathology or cytology were divided into two groups randomly,45 cases in GN group treated with gemcitabine and nedaplatin.Administration method：Gem 800mg/m^2,d1,8,15,iv drip;NDP 80-100mg/m^2,d1,iv drip.Other 45 cases in GP group treated with gemcitabine and cisplatin.Administration method：Gem 800mg/m^2,d1,8,15,iv drip;DDP 25mg/m^2,d1-3,iv drip.All patients were undergone 2 cycles,each cycle 28 days.Results： The total effective rate of GN group was 37.8%,GP group 40.0%（P〉0.05）.The median survival time of GN group was 8.8 months,GP group 9.0 months（P〉0.05）.Incidence of the GN group with nausea and vomiting was lower than that of the GP group（P〈0.05）.Conclusion： GN regimen and GP regimen are similarly in the clinical effect and the median survival time.Moreover GN regimen has lower incidence of nausea or vomiting.